One of few books to cover all aspects of cyclin-dependent kinases (CDKs), this volume examines CDKs as molecular and functional entities, their role in various disease processes, and their potential for pharmacological modulation. The book first explains the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors. Then it examines the design, development, and chemistry of small molecule CDK inhibitors. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future prospects of CDK inhibitors as anticancer agents.

One of few books to cover all aspects of cyclin-dependent kinases (CDKs), this volume examines CDKs as molecular and functional entities, their role in various disease processes, and their potential for pharmacological modulation. The book first explains the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors. Then it examines the design, development, and chemistry of small molecule CDK inhibitors. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future prospects of CDK inhibitors as anticancer agents.

One of few books to cover all aspects of cyclin-dependent kinases (CDKs), this volume examines CDKs as molecular and functional entities, their role in various disease processes, and their potential for pharmacological modulation. The book first explains the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors. Then it examines the design, development, and chemistry of small molecule CDK inhibitors. The final section assesses the current status of CDK inhibitors in clinical trials, the therapeutic deployment challenges of small molecule inhibitors, and the future prospects of CDK inhibitors as anticancer agents.